Troels Koch (TK) is CTO and Head of Chemistry at MiNA Therapeutics. TK has 25 years’ experience in the international life science and biopharmaceutical industry. Founder of several biotech companies of which Exiqon A/S and Santaris Pharma A/S are the most known. Santaris Pharma A/S was acquired by Roche in August 2014 and after the acquisition, TK was leading LNA research both in Copenhagen (RICC) and in Basel (Roche, Switzerland). TK pioneered LNA therapeutics and has positioned LNA antisense science and technology at an international lead position and taken an active role in all steps of oligonucleotide drug discovery and development. In his current role as CTO and Head of Chemistry at MiNA Therapeutics the focus is to improve the drug properties of gene activating oligonucleotides employing advanced sets of chemical modifications. TK has built R&D organizations up to 75 co-workers, held >100 invited presentations at international conferences and is author of 90 peer reviewed publications.